These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34710285)

  • 21. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
    Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
    Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
    Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
    Front Oncol; 2022; 12():761558. PubMed ID: 35237506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
    Parker BM; Parker JV; Lymperopoulos A; Konda V
    J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory myofibroblastic tumors of the central nervous system that express anaplastic lymphoma kinase have a high recurrence rate.
    Denis DJ; Elayoubi K; Weil AG; Berthelet F; Bojanowski MW
    Surg Neurol Int; 2013; 4():70. PubMed ID: 23776756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinicopathological features of inflammatory myofibroblastic tumor].
    Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
    [No Abstract]   [Full Text] [Related]  

  • 26. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.
    Saiki M; Ohyanagi F; Ariyasu R; Koyama J; Sonoda T; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Ninomiya H; Ishikawa Y; Nishio M
    Jpn J Clin Oncol; 2017 Dec; 47(12):1189-1192. PubMed ID: 28977547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report.
    Xu X; Li H; Peng K; Yu Y; Chen L; Fang Y; Sun Y; Hou Y; Liu T
    Oncol Lett; 2019 Feb; 17(2):2370-2376. PubMed ID: 30675302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors.
    Trahair T; Gifford AJ; Fordham A; Mayoh C; Fadia M; Lukeis R; Wood AC; Valvi S; Walker RD; Blackburn J; Heyer EE; Mercer TR; Barbaric D; Marshall GM; MacKenzie KL
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study.
    Cook JR; Dehner LP; Collins MH; Ma Z; Morris SW; Coffin CM; Hill DA
    Am J Surg Pathol; 2001 Nov; 25(11):1364-71. PubMed ID: 11684952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor.
    Kaino A; Niizuma H; Katayama S; Irie M; Nakano T; Sato D; Saito T; Kato S; Suehara Y; Sasahara Y; Kikuchi A
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30330. PubMed ID: 37017194
    [No Abstract]   [Full Text] [Related]  

  • 31. Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy.
    Nakano K
    Jpn J Clin Oncol; 2023 Oct; 53(10):885-892. PubMed ID: 37394916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single- Center Study.
    Liu X; Gong C; Zhang J; Feng W; Guo Y; Sang Y; Wang C; Chen Y; Wang J; Yu L; Zhang X; Luo Z
    Cancer Res Treat; 2023 Jul; 55(3):1001-1010. PubMed ID: 36915248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaplastic Lymphoma Kinase Positive Mesenteric Inflammatory Myofibroblastic Tumor in Adult Woman.
    Lee CS; Kim JS; Rodriguez R; Krell RW
    Cureus; 2022 Apr; 14(4):e24422. PubMed ID: 35637807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification.
    Wang K; Guo R; Siegal GP; Wei S
    Pathol Res Pract; 2019 Sep; 215(9):152535. PubMed ID: 31326196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory Myofibroblastic Tumor Driven by Novel
    Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
    J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS.
    Vidrine DW; Berry JF; Garbuzov A; Falcon C; Tubbs RS; Bui CJ
    Childs Nerv Syst; 2021 Jul; 37(7):2147-2151. PubMed ID: 34014367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation.
    Zhao S; Liu W; Li S; Shi T; Chen Q; Li Q; Sun L; Ren D; Song Z; Huang C; Xu S
    Cancer Res Treat; 2021 Apr; 53(2):601-606. PubMed ID: 33091968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring
    Zhao T; Zhang X; Liu X; Ren M; Cheng Y; Wang J; Luo Z
    Front Oncol; 2023; 13():1147974. PubMed ID: 37035208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Locally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review.
    Durham C; Clemons M; Alias A; Konduri K
    Cureus; 2022 Jul; 14(7):e27223. PubMed ID: 36035049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
    Gambacorti-Passerini C; Orlov S; Zhang L; Braiteh F; Huang H; Esaki T; Horibe K; Ahn JS; Beck JT; Edenfield WJ; Shi Y; Taylor M; Tamura K; Van Tine BA; Wu SJ; Paolini J; Selaru P; Kim TM
    Am J Hematol; 2018 May; 93(5):607-614. PubMed ID: 29352732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.